ERBB2 and hematopoietic and lymphoid cell neoplasm: Rituximab (a mAb specific to the B cell marker CD20), trastuzumab (anti-ErbB2/HER2 mAb) and cetuximab (an anti-EGFR mAb) have proved marked efficacies in the treatment of various solid and hematological tumors [22].